Edwards Lifesciences (EW) Tops Q4 EPS by 1c; Guides Above the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Edwards Lifesciences Reports Fourth Quarter Results
February 2, 2016 4:15 PM ESTIRVINE, Calif., Feb. 2, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2015.
Â
Fourth Quarter and Recent Highlights:
Global sales grew 8.6% to $671.1 million, and underlying1 sales were up 15.1%. Global THV sales grew 25.0%, and underlying sales were up 32.4%. Results reflect 2-for-1 stock split completed in December 2015. GAAP EPS was $0.64, an increase of 28.0%, and non-GAAP EPS grew... More